Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
86. |
ECCT/21/09/04 | Recombinant COVID-19 Vaccine A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells) for the prevention of COVID-19 in adults aged 18 years and older |
Principal Investigator(s) 1. Sylvester Kimaiyo Site(s) in Kenya 1. KAVI-Institute of Clinical Research (Nairobi City county) 2. Moi Teaching and Referral Hospital (Uasin Gishu county) 3. Kenya Medical Research Institute, Kilifi (Kilifi county) |
View |
87. |
ECCT/21/09/01 | Kuwa Free! - Live free! Co-benefits of co-delivery of long-acting antiretrovirals and contraceptives |
Principal Investigator(s) 1. Rena Patel 2. Edwin Were Site(s) in Kenya Moi Teaching and Referral Hospital |
View |
88. |
ECCT/21/08/01 | CARES Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety,and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa. |
Principal Investigator(s) 1. JOSPHAT KOSGEI Site(s) in Kenya 1. AMPATH Eldoret (Uasin Gishu county) 2. Aghakhan University (Nairobi City county) 3. Kericho KEMRI WRP CRC site (Kericho county) |
View |
89. |
ECCT/21/07/06 | GBT132_Inclacumab-Ps 3 Trial A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises. |
Principal Investigator(s) 1. Fredrick Asirwa Chite 2. Videlis N Nduba 3. Bernhards Ragama Ogutu Site(s) in Kenya 1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 2. KEMRI/CRDR (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Strathmore University Medical Centre (Nairobi City county) |
View |
90. |
ECCT/21/07/05 | CARES A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine from Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa |
Principal Investigator(s) 1. Dr Reena Shah Site(s) in Kenya 1. Aga Khan University Hospital Nairobi (Nairobi City county) 2. KEMRI Walter Reed Project (Kericho county) 3. Moi University Clinical Research Centre (Uasin Gishu county) |
View |